Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, has announced that the Company will be attending and presenting at the ShareSoc Growth Company Seminar on February 25, 2020 at DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester M1 3DG.
Cathal Friel, Open Orphan’s Executive Chairman will be presenting from 18:40 onwards to update existing and potential investors on the Company’s business plans for 2020.
The event will provide an opportunity for investors to hear about the progress being made by the Company following the acquisition of hVIVO and the potential for Open Orphan as it moves rapidly forward rapidly. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services ,and supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all of which are particularly relevant and topical in the environment of heightened awareness in light of the current outbreak of coronavirus disease (COVID-19).It also has Europe’s only commercial 24 bed quarantine clinic and on site virology laboratory at Queen Mary’s Hospital in London.
A link to our investor presentation is already available on our website at https://www.openorphan.com/sites/openorphan/files/Open_Orphan_Investor_Deck_0120_1.pdf
Additionally, a link to the video of Open Orphan’s presentation will be made available on the Company website following the event.
For further information on the Shares Investor Evening and registration, please visit the event website https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-25-february-2020/